Pangaea Biotech, USP Dexeus University Institute, Barcelona, Spain.
J Transl Med. 2010 Dec 18;8:135. doi: 10.1186/1479-5876-8-135.
Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients.
EGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non-small-cell lung cancer (NSCLC) cell lines and tumor samples from 78 stage IV NSCLC patients.
IHC correctly identified del 19 in the H1650 and PC9 cell lines, L858R in H1975, and wild-type EGFR in H460 and A549, as well as wild-type EGFR in tumor samples from 22 patients. IHC with the mAb against EGFR with del 19 was highly positive for the protein in all 17 patients with a 15-bp (ELREA) deletion in exon 19, whereas in patients with other deletions, IHC was weakly positive in 3 cases and negative in 9 cases. IHC with the mAb against the L858R mutation showed high positivity for the protein in 25/27 (93%) patients with exon 21 EGFR mutations (all with L858R) but did not identify the L861Q mutation in the remaining two patients.
IHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients. However these mAbs should be validated with additional studies to clarify their possible role in routine clinical practice for screening EGFR mutations in NSCLC patients.
免疫组织化学（IHC）与突变特异性抗体可能是检测肺癌患者表皮生长因子受体（EGFR）突变的辅助方法。
通过 DNA 检测分析 EGFR 突变状态，并与 5 种非小细胞肺癌（NSCLC）细胞系和 78 例 IV 期 NSCLC 患者肿瘤样本的 IHC 结果进行比较。
IHC 正确鉴定了 H1650 和 PC9 细胞系中的 del19、H1975 中的 L858R 以及 H460 和 A549 中的野生型 EGFR，也正确鉴定了 22 例患者肿瘤样本中的野生型 EGFR。针对 EGFR 缺失 19 的 mAb 对 17 例存在 15 个碱基对（ELREA）缺失的患者的蛋白具有高度阳性反应，而在其他缺失的患者中，3 例呈弱阳性，9 例呈阴性。针对 EGFR L858R 突变的 mAb 对 27 例（93%）存在 EGFR 外显子 21 突变（均为 L858R）的患者的蛋白具有高度阳性反应，但未能鉴定出另外 2 例患者中的 L861Q 突变。
针对 EGFR 的突变特异性 mAb 的 IHC 是检测 NSCLC 患者 EGFR 突变的一种很有前途的方法。然而，这些 mAb 应通过额外的研究进行验证，以明确它们在常规临床实践中筛选 NSCLC 患者 EGFR 突变中的可能作用。
